Abivax SA ADS/$ABVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abivax SA ADS
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Ticker
$ABVX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
69
ISIN
US00370M1036
Website
Abivax SA ADS Metrics
BasicAdvanced
$369M
-
-$3.14
1.12
-
Price and volume
Market cap
$369M
Beta
1.12
52-week high
$8.47
52-week low
$4.77
Average daily volume
155K
Financial strength
Current ratio
1.816
Quick ratio
1.702
Long term debt to equity
161.268
Total debt to equity
269.116
Interest coverage (TTM)
-52.39%
Management effectiveness
Return on assets (TTM)
-40.62%
Return on equity (TTM)
-148.95%
Valuation
Price to revenue (TTM)
29.497
Price to book
8.07
Price to tangible book (TTM)
21.05
Price to free cash flow (TTM)
-2.058
Growth
Revenue change (TTM)
173.28%
Earnings per share change (TTM)
-18.51%
3-year revenue growth (CAGR)
36.93%
3-year earnings per share growth (CAGR)
0.58%
Abivax SA ADS News
AllArticlesVideos
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
GlobeNewsWire·1 month ago
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
GlobeNewsWire·1 month ago
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abivax SA ADS stock?
Abivax SA ADS (ABVX) has a market cap of $369M as of May 30, 2025.
What is the P/E ratio for Abivax SA ADS stock?
The price to earnings (P/E) ratio for Abivax SA ADS (ABVX) stock is 0 as of May 30, 2025.
Does Abivax SA ADS stock pay dividends?
No, Abivax SA ADS (ABVX) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Abivax SA ADS dividend payment date?
Abivax SA ADS (ABVX) stock does not pay dividends to its shareholders.
What is the beta indicator for Abivax SA ADS?
Abivax SA ADS (ABVX) has a beta rating of 1.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.